Pfizer Inc. (PFE) shares advanced on Thursday, gaining approximately 2.7% to trade at $26.28 by late morning. The uptick came after RBC Capital Markets raised its rating on the pharmaceutical giant from Underperform to Sector Perform, while maintaining a $25 price target. The upgrade reflects a more balanced risk-reward profile following recent share price declines, according to RBC analysts.
The stock opened the session at $25.85, fluctuated between a low of $25.61 and a high of $26.48, and saw trading volume exceed 15.6 million shares by late morning. Pfizer's performance outpaced the broader market: the SPDR S&P 500 ETF Trust (SPY) rose 0.38%, and the Health Care Select Sector SPDR Fund (XLV) added 0.81%.
Despite the positive rating change, investor sentiment remains cautious due to emerging policy headwinds from Europe. Reuters reported that Pfizer CEO Albert Bourla sent a letter to German Chancellor Friedrich Merz on June 9, indicating that the company is reassessing the timing and scale of planned investments in Germany. The reassessment stems from a proposed drug-price reduction policy that could significantly impact pharmaceutical companies' profitability in the region.
Bourla's letter did not specify which investments are under review, and Pfizer declined further comment. The German pricing risk adds to broader global concerns over drug pricing pressures, particularly in the United States, where policy debates continue to influence where pharmaceutical firms allocate capital. The Reuters report noted that Eli Lilly (LLY) halved a planned $2.3 billion investment in Germany, and Boehringer Ingelheim dropped €900 million in spending plans, both citing expected healthcare spending cuts.
Wall Street's risk appetite improved on Thursday, with major indices climbing. The Dow Jones Industrial Average rose 0.90%, the S&P 500 gained 0.81%, and the Nasdaq Composite advanced 1.07% by early afternoon, driven by a rebound in technology stocks.
Pfizer's fundamentals remain a key focus for investors. The company reported first-quarter 2026 revenue of $14.45 billion, a 5% year-over-year increase, with adjusted diluted earnings per share of $0.75. Management maintained its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted EPS projection of $2.80 to $3.00. The dividend, currently $0.43 per share quarterly, yields over 6%, and Pfizer returned $2.4 billion to shareholders via cash dividends in the first quarter. However, share repurchases were excluded from 2026 guidance.
Analyst consensus on Pfizer remains mixed. According to Benzinga's tracker, the stock carries a Hold-like overall rating, while Google Finance data shows 8 Buy, 13 Hold, and 2 Sell ratings, with a 12-month average price target of $29.05. The stock currently trades near the midpoint of its 52-week range of $23.11 to $28.74.
Looking ahead, Pfizer's ability to sustain its 2026 forecast, advance its pipeline, and navigate European pricing pressures will be critical for its post-COVID growth trajectory. The German policy risk underscores the ongoing challenges for global pharmaceutical companies in balancing investment plans with regulatory and pricing uncertainties.
